FRANKFURT (Reuters) - Werner Wenning, chief executive of German drug and chemicals group Bayer (BAYG.DE: Quote, Profile, Research, Stock Buzz), declined to comment when asked about possible interest in drugmaker Schering (SCHG.DE: Quote, Profile, Research, Stock Buzz) at the Reuters Chemicals Summit.
But he said he saw consolidation in the pharmaceuticals and healthcare sectors continuing around the world.
"This consolidation process will continue from a global perspective," Wenning said at the summit at the Reuters office in Frankfurt. He added that the company expected "very intensive consolidation" in the over-the-counter health business.
German drugs and chemicals group Merck (MRCG.DE: Quote, Profile, Research, Stock Buzz) has made an unsolicited bid for Schering, which the Schering management has rebuffed.
© Thomson Reuters 2008. All rights reserved.
| Paper | Aug 20 - 21, 2008 | Manufacturing |
| Japan Investment | Jul 01 - 2, 2008 | Country Summits |
| Global Real Estate | Jun 23 - 25, 2008 | Real Estate |
| Consumer and Retail | Jun 16 - 18, 2008 | Consumer Retail |
| Investment Outlook | Jun 09 - 12, 2008 | Financial Services / Exchanges |
